Abstract Interleukin-2 (IL-2) was historically one of the few treatments for adults with stage IV
solid tumors that could produce complete responses (CRs) that were often durable for …

Background Hypomethylating agents are used to treat cancers driven by aberrant DNA
methylation, but their short half-life might limit their activity, particularly in patients with less …

Abstract High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal
cell carcinoma (mRCC) in 1992 and for metastatic melanoma (mM) in 1998, in an era …

BACKGROUND Outcomes for patients with relapsed or refractory acute myeloid leukemia
(AML) are poor. Guadecitabine, a next‐generation hypomethylating agent, could be useful …

Background and aims Pilot studies with visilizumab, a humanised monoclonal antibody to
CD3, suggest efficacy for corticosteroid-refractory ulcerative colitis (UC). A placebo …

• Ninety central venous catheters were inserted into 80 patients undergoing therapy for
malignant neoplasms. Bacteremia and fungemia occurred in 18 of 41 treatment courses in …

Background: Visilizumab is a humanized IgG2 monoclonal anti‐CD3 antibody. We
evaluated its safety and dose response in severe intravenous steroid‐refractory ulcerative …

Aims: A combination of oral decitabine (DAC), a drug normally parenterally administered,
with an oral cytidine deaminase inhibitor (CDAi), enhances its bioavailability. An oral version …

DNA hypomethylating agents (DHAs) play a well-acknowledged role in potentiating the
immunogenicity and the immune recognition of neoplastic cells. This immunomodulatory …

Before administration of intensive cytotoxic therapy, 90 central venous catheters were
inserted into 80 patients with malignancies. Twenty‐seven episodes of bacteremia and …